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A B S T R A C T
Background
Kidney transplantation is the treatment of choice for patients with end-stage kidney disease. In a previous review we concluded that the
routine use of ureteric stents in kidney transplantation reduces the incidence of major urological complications (MUC). Unfortunately,
this reduction appears to lead to a concomitant rise in urinary tract infections (UTI). For kidney recipients UTI is now the commonest
post-transplant complication. This represents a considerable risk to the immunosuppressed transplant recipient, particularly in the era
of increased immunologically challenging transplants. There are a number of different approaches taken when considering ureteric
stenting and these are associated with differing degrees of morbidity and hospital cost.
Objectives
This review aimed to look at the benefits and harms of early versus late removal of the ureteric stent in kidney transplant recipients.
Search methods
We searched the Cochrane Kidney and Transplant Specialised Register up to 27 March 2017 through contact with the Information
Specialist using search terms relevant to this review. Studies contained in the Specialised Register are identified through search strategies
specifically designed forCENTRAL,MEDLINE, andEMBASE; handsearching conference proceedings; and searching the International
Clinical Trials Register Search Portal and ClinicalTrials.gov.
Selection criteria
All RCTs and quasi-RCTs were included in our meta-analysis. We included recipients of kidney transplants regardless of demography
(adults or children) or the type of stent used.
Data collection and analysis
Two authors reviewed the identified studies to ascertain if they met inclusion criteria. We designated removal of a ureteric stent before
the third postoperative week (< day 15) or during the index transplant admission as “early” removal. The studies were assessed for
quality using the risk of bias tool. The primary outcome of interest was the incidence of MUC. Further outcomes of interest were
the incidence of UTI, idiosyncratic stent-related complications, hospital-related costs and adverse events. A subgroup analysis was
performed examining the difference in complications reported depending on the type of ureteric stent used; bladder indwelling (BI)
versus per-urethral (PU). Statistical analyses were performed using the random effects model and results expressed as relative risk (RR)
with 95% confidence intervals (CI).
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Main results
Five studies (1127 patients) were included in our analysis. Generally the risk of bias of the included studies was judged low or unclear;
they addressed the research question and utilised a prospective randomised design. It is uncertain whether early stent removal verus late
stent removal improved the incidence of MUC (5 studies, 1127 participants: RR 1.87, 95% CI 0.61 to 5.71; I2 = 21%; low certainty
evidence). The incidence of UTI may be reduced in the early stent removal group (5 studies, 1127 participants: RR 0.49 95% CI 0.30
to 0.81; I2 = 59%; moderate certainty evidence). This possible reduction in the UTI incidence was only apparent if a BI stent was used,
(3 studies, 539 participants, RR 0.45 95% CI 0.29 to 0.70; I2 = 13%; moderate certainty evidence). However, if an externalised PU
stent was used there was no discernible difference in UTI incidence between the early and late group (2 studies, 588 participants: RR
0.60 95% CI 0.17, 2.03; I2 = 83%; low certainty evidence). Data on health economics and quality of life outcomes were lacking.
Authors’ conclusions
Early removal of ureteric stents following kidney transplantation may reduce the incidence of UTI while it uncertain if there is a higher
risk of MUC. BI stents are the optimum method for achieving this benefit.
P L A I N L A N G U A G E S U M M A R Y
Early versus late ureteric stent removal after kidney transplantation
What is the issue?
The ureter drains urine from the kidney into the bladder and has to be reconnected during kidney transplantation. To protect this new
connection the operating surgeon places a plastic stent inside the ureter to help it heal. Routinely this stent would be left in place for up
to three months. However, this is associated with an increased risk of urine infection which can be high-risk for transplant recipients
whose immune system is suppressed through anti-rejection medication. If this stent could be removed earlier then the risk of infection
may be reduced but would it be associated with major urological complications e.g. urine leak or obstruction.
What did we do?
This study was designed to review all the previously published research in this area to determine the answer to this question. Five studies
including 1097 patients were identified.
What did we find?
It is uncertain whether the number of major urological complications were different in those patients whose stent was removed early
(less than 15 days post-operatively), when compared with those removed later (more than 15 days post-operatively). The number of
patients suffering from a urinary tract infection may be less in the early removal group - especially if the stent was not exposed to the
external environment. The studies identified for this review were generally of poor quality.
Conclusions
It is uncertain whether a bladder indwelling ureteric stent that is removed early following kidney transplantation reduces the risk of
complications, however it may prevent urine tract infections.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Early versus late ureteric stent removal after kidney transplantation
Patient or population: kidney transplant recipients
Intervention: early ureteric stent removal
Comparison: late ureteric stent removal
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95%CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Risk with late removal Risk with early removal
Major urological complica-
t ions: all stents
follow-up range: 3 to 12
months
Study populat ion RR 1.87
(0.61 to 5.71)
1127 (5) ⊕⊕⊕⊕
LOW 1
12 per 1,000 23 per 1,000
(7 to 69)
Major urological complica-
t ions: bladder indwelling
stents
follow-up range: 3 months
to 12 months
Study populat ion RR 1.67
(0.52 to 5.36)
539 (3) ⊕⊕⊕⊕
LOW 1
15 per 1,000 24 per 1,000
(8 to 79)
Major urological complica-
t ions: per-urethral stents
follow-up range: 3 months
to 12 months
Study populat ion RR 1.51
(0.03 to 74.45)
588 (2) ⊕⊕⊕⊕
LOW 1
10 per 1,000 15 per 1,000
(0 to 732)
Urinary tract infect ion: all
stents
Study populat ion RR 0.49
(0.30 to 0.81)
1126 (5) ⊕⊕⊕©
MODERATE 12
185 per 1,000 91 per 1,000
(56 to 150)
Urinary tract infect ion: blad-
der indwelling stents
Study populat ion RR 0.45
(0.29 to 0.70)
539 (3) ⊕⊕⊕©
MODERATE 12
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209 per 1,000 94 per 1,000
(61 to 146)
Urinary tract infect ion: per-
urethral stents
Study populat ion RR 0.60
(0.17 to 2.03)
587 (2) ⊕⊕©©
LOW 12
164 per 1,000 98 per 1,000
(28 to 333)
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; RR: Risk rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 All studies were unblinded, however, this was unavoidable given the nature of the intervent ion. The majority of studies
provided minimal information on processes of randomisat ion and allocat ion
2 Inconsistent def init ion and variable report ing of urinary tract infect ion across included studies
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B A C K G R O U N D
Description of the condition
Kidney transplantation is the treatment of choice for patients with
end-stage kidney disease (ESKD). Over the last four decades, sur-
gical techniques have been refined and the majority standardised.
In current surgical practice there remains very little variation be-
tween centres and surgeons in most aspects of kidney transplant
surgery. The anastomosis created between the donor transplant
ureter and the bladder remains one aspect of surgical practicewhere
techniques continue to evolve (Nicholson 1991). In a previous
review we focused on the role of the ureteric stent and its function
in reducing major urological complications (MUC), urinary leak
or fistula and ureteric stenosis (Wilson 2013). We concluded that
the universal use of stents reduces the incidence of MUC from
between 7% and 9%, to 1.5%. Unfortunately, this reduction ap-
pears to lead to a concomitant rise in urinary tract infections (UTI)
which is offset by the use of antibiotics. In addition, stents are asso-
ciated with idiosyncratic complications (migration, malposition,
haematuria, encrustation, irritative bladder symptoms, andmay be
forgotten) (Bardapure 2014). More recently there have also been
some isolated reports of an association between the use of ureteric
stents and the incidence of an opportunistic viral pathogen - BK
virus (Siparsky 2011), consequent to its negative effects on distal
ureteric motility.
Description of the intervention
Ureteric stents used in transplantation can be of different lengths
(12 cm to 36 cm), calibres (5F to 7F) and designs (percutaneous
(PC), per-urethral (PU), or bladder indwelling (BI)). Most centres
have traditionally placed BI stents for a period of four weeks to
three months before removal in an operating room using a flex-
ible cystoscope under local anaesthetic, or if it is combined with
another procedure such as haemodialysis fistula ligation, under
general anaesthetic (Wilson 2013). This approach necessitates a
further admission to hospital and hospital costs.
Several approaches have been suggested to maximise the benefit
of stents and reduce morbidity, costs or both. One option is to
remove the stent before the patient leaves hospital (a period of
only one or two weeks) (Indu 2012; Thiyagarajan 2012), another
is to use a PC or PU stent which can be removed in the ward or
outpatient clinic (Olsburgh 2010). A further option is to tie the BI
stent to the urinary catheter (Morris-Stiff 1998) and remove them
simultaneously (week 1). On the basis of these descriptions and
standard practices we arbitrarily designated removal of a ureteric
stent before the third postoperative week (< day 15) or during the
index transplant admission as “early” removal.
How the intervention might work
Ureteric stents seem to reduce MUC in two phases. At initial
placement ureteric stents help the surgeon by reducing anatomical
kinking and delineating the lumen to aid in suture placement. Af-
ter implantation, inflammation and oedema can cause obstruction
at the anastomosis, and the stent helps urine drain from the kidney
into the bladder, reducing intra-ureteric pressure. This may also
aid in preventing Ischaemic-related necrosis of the distal ureter
and subsequent urine leak.
However, as a foreign body, ureteric stents rapidly become
colonised with a biofilm of micro-organisms that may predispose
toUTI in the recipient bladder andpyelonephritis due to backflow
of urine into the kidney pelvis during bladder detrusor contrac-
tion (Waters 2008). In this respect, early removal with the urinary
catheter may be considered a significant advantage. PC stents, or
PU stents that run beside the urinary catheter, offer the advantage
of being able to monitor transplant urine output independently of
the native kidney output, thus differentiating between immediate
and delayed graft function. This is certainly useful for research
studies on ischaemic-reperfusion injury, but of dubious clinical
significance in the short term.
Why it is important to do this review
Live donor kidney transplantation is becoming more widespread
as the waiting time for cadaveric transplantation lengthens. As a
result ABO-incompatible transplantation is more common and
recipients treated with higher intensity immunosuppression are
at increased risk of peri-operative complications. In one registry
review of patients undergoing live donor kidney transplantation,
UTI was the most common complication, with an incidence over
30% (Montgomery 2012). Some surgeons believe that the benefit
of ureteric stents is only within the first one or two weeks after
transplantation, and that leaving them in situ for longer leads to the
potential for stent-related morbidity such as UTI, the possibility
of being forgotten, and the risk of severe urosepsis on removing a
late encrusted stent at four to six weeks (Bardapure 2014). Other
clinicians believe that ischaemic necrosis or stenosis of the ureter
is a delayed event and that an indwelling stent can prevent these
complications only by being left for longer periods of time.
This review attempted to dissect differences in ureteric morbidity
by meta-analysing data from studies differentiated by the length
of time stents were left in situ.
O B J E C T I V E S
This review aimed to look at the benefits and harms of early (be-
fore the third postoperative week (< day 15) or during the index
transplant admission as “early” removal) versus late removal of the
ureteric stent in kidney transplant recipients.
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M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials (RCTs) and quasi-RCTs (RCTs
in which allocation to treatment was obtained by alternation, use
of alternate medical records, date of birth or other predictable
methods) looking at timing of ureteric stent removal in kidney
transplantation.
Types of participants
Inclusion criteria
We included recipients of kidney transplants regardless of demog-
raphy (adults or children) or the type of stent placed. To adequately
assess studies the protocols should include data on the allocation
and randomisation status of patients or kidneys with complex uri-
nary tracts (bladder diversion, duplex ureters, en bloc transplants).
Multivisceral recipients in whom a kidney is combined with other
organs (e.g. liver or pancreas) are also included.
Exclusion criteria
Studies including patients with stenting of ileal conduits or con-
tinent urinary diversions were excluded.
Types of interventions
We investigated the timing of stent removal (early versus late) after
kidney transplantation. Ureteric stents used in transplantation can
be of different lengths (12 cm to 36 cm), calibres (5F to 7F)
and designs (PC, PU, BI) (Wilson 2013). This review addressed
the question of whether the stent can be removed sooner and
reduce morbidity as well as associated hospital costs. We have also
attempted to address the following questions.
1. PC versus BI stents
2. PU versus PC stents
3. BI versus PU stents
Types of outcome measures
MUC and UTI are the most important outcomes relevant to this
review. MUC is a post-operative surgical complication usually as-
sociated with the vesicoureteric anastomosis. MUC is defined as
any urological complication arising within the first 6 months fol-
lowing kidney transplantation that requires an intervention or re-
operation e.g. urinary obstruction, leak, fistula or stenosis. This
includes temporary placement of nephrostomy. We also consid-
ered:
1. Stent-related complications (e.g. irritation, migration,
malposition, haematuria, encrustation, irritative bladder
symptoms, forgotten stents)
2. Hospital-related costs including hospital stay, re-operation,
surgical re-implantation
3. Adverse events related to stent removal (urosepsis,
haematuria, rare graft loss, BK virus nephropathy)
4. Graft and patient survival.
Primary outcomes
The primary outcomes of importance were MUC and UTI inci-
dence; and for all included studies, this was the minimum data set
accepted.
Secondary outcomes
The secondary outcomes were stent-related complications, hospi-
tal-related costs and adverse events related to stent removal. The
concept of treatment failure is also relevant, where an operatively
placed PC or PU stent is replaced with a BI stent during the op-
eration
Search methods for identification of studies
Electronic searches
We searched the Cochrane Kidney and Transplant Specialised
Register up to 27 March 2017 through contact with the Infor-
mation Specialist using search terms relevant to this review. The
Cochrane Kidney and Transplant Specialised Register contains
studies identified from several sources.
1. Monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL)
2. Weekly searches of MEDLINE OVID SP
3. Handsearching of kidney-related journals and the
proceedings of major kidney conferences
4. Searching of the current year of EMBASE OVID SP
5. Weekly current awareness alerts for selected kidney and
transplant journals
6. Searches of the International Clinical Trials Register
(ICTRP) Search Portal and ClinicalTrials.gov.
Studies contained in the SpecialisedRegister are identified through
search strategies for CENTRAL,MEDLINE, andEMBASE based
on the scope of Cochrane Kidney and Transplant. Details of these
strategies, as well as a list of handsearched journals, conference
proceedings and current awareness alerts, are available in the Spe-
cialised Register section of information about Cochrane Kidney
and Transplant.
See Appendix 1 for search terms used in strategies for this review.
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Searching other resources
1. Reference lists of review articles, relevant studies and
clinical practice guidelines.
2. Letters seeking information about unpublished or
incomplete studies to investigators known to be involved in
previous studies.
Data collection and analysis
Selection of studies
The search strategy described was used to obtain titles and ab-
stracts of studies that were relevant to the review. The titles and
abstracts were screened independently by two authors, who dis-
carded studies that were not applicable; however studies and re-
views that included relevant data or information on studies were
retained initially. Two authors independently assessed retrieved ab-
stracts and, if necessary the full text, of these studies to determine
which studies satisfied the inclusion criteria.
Data extraction and management
Data extraction was carried out independently by two authors
using standard data extraction forms. There were no non-English
language studies. Where more than one publication of one study
existed, reportswere grouped together and the publicationwith the
most complete data used in the analyses.Where relevant outcomes
were only published in earlier versions these data was used. Any
discrepancy between published versions has been highlighted.
Assessment of risk of bias in included studies
The following items were independently assessed by two authors
using the risk of bias assessment tool (Higgins 2011) (see Appendix
2) and depicted graphically using the RevMan “Risk of bias” tools.
• Was there adequate sequence generation (selection bias)?
• Was allocation adequately concealed (selection bias)?
• Was knowledge of the allocated interventions adequately
prevented during the study?
◦ Participants and personnel (performance bias)
◦ Outcome assessors (detection bias)
• Were incomplete outcome data adequately addressed
(attrition bias)?
• Are reports of the study free of suggestion of selective
outcome reporting (reporting bias)?
• Was the study apparently free of other problems that could
put it at a risk of bias?
Measures of treatment effect
For dichotomous outcomes (MUC, UTI) results are expressed as
risk ratio (RR) with 95% confidence intervals (CI). There were no
comparative meta-analysis data using continuous scales of mea-
surement.
Unit of analysis issues
We did not encounter any specific unit of analysis issues; specifi-
cally no studies using cluster randomisation or cross-over alloca-
tion.
Dealing with missing data
Any further information required from the original author was
requested by written correspondence (e.g. emailing corresponding
author/s) and any relevant information obtained in this manner
was to be included in the review. Evaluation of important numer-
ical data such as screened, randomised patients as well as inten-
tion-to-treat, as-treated and per-protocol population was carefully
performed. Attrition rates, for example drop-outs, losses to fol-
low-up and withdrawals were investigated. Issues of missing data
and imputation methods (for example, last-observation-carried-
forward (LOCF)) was to be critically appraised (Higgins 2011).
Due to the paucity of data across multiple comparisons “missing
data” computations were not considered appropriate.
Assessment of heterogeneity
Wefirst assessed the heterogeneity by visual inspection of the forest
plot. Heterogeneity was then analysed using a Chi2 test on N-
1 degrees of freedom, with an alpha of 0.05 used for statistical
significance and with the I2 test (Higgins 2003). A guide to the
interpretation of I2 values is as follows.
• 0% to 40%: might not be important
• 30% to 60%: may represent moderate heterogeneity
• 50% to 90%: may represent substantial heterogeneity
• 75% to 100%: considerable heterogeneity.
The importance of the observed value of I2 depends on the mag-
nitude and direction of treatment effects and the strength of evi-
dence for heterogeneity (e.g. P-value from the Chi2 test, or a con-
fidence interval for I2) (Higgins 2011).
Assessment of reporting biases
Funnel plots were to be used to assess for the potential existence of
small study bias, however there were insufficient studies identified
to do this (Higgins 2011).
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Data synthesis
Data were pooled using the random-effects model, but the fixed-
effectmodel was also used to ensure robustness of themodel chosen
and susceptibility to outliers.
Subgroup analysis and investigation of heterogeneity
Subgroup analysis was used to explore possible sources of hetero-
geneity, for example, type of solid organ transplanted and study
quality. Heterogeneity among participants could be related to age,
gender, co-morbidities and underlying diseased organ pathology.
Heterogeneity in treatments could be related to the type of stent,
route of insertion, duration of placement, antibiotic regime, or
mechanism of removal.
Adverse effects were tabulated and assessed with descriptive tech-
niques, as theywere likely to be different for the various techniques
used. Where possible, the risk difference with 95% CI was to be
calculated for each adverse effect, either compared to long term
stent or to another stent technique. If enough studies were iden-
tified we planned to investigate the following clinically relevant
subgroup analyses by technique:
• PC versus BI stents
• PU versus PC stents
• BI versus PU stents
Sensitivity analysis
We performed sensitivity analyses in order to explore the influence
of the following factors on effect size.
• Repeating the analysis excluding unpublished studies;
• Repeating the analysis taking account of risk of bias, as
specified above;
• Repeating the analysis excluding any very long or large
studies to establish how much they dominate the results;
• Repeating the analysis excluding studies using the following
filters: diagnostic criteria, language of publication and country.
’Summary of findings’ tables
We have presented the main results of the review in ’Summary of
findings’ tables. These tables present key information concerning
the quality of the evidence, the magnitude of the effects of the
interventions examined, and the sum of the available data for the
main outcomes (Schünemann 2011a). The ’Summary of findings’
tables also include an overall grading of the evidence related to
each of the main outcomes using the GRADE (Grades of Recom-
mendation, Assessment, Development and Evaluation) approach
GRADE 2008. The GRADE approach defines the quality of a
body of evidence as the extent to which one can be confident that
an estimate of effect or association is close to the true quantity
of specific interest. The quality of a body of evidence involves
consideration of within-trial risk of bias (methodological quality),
directness of evidence, heterogeneity, precision of effect estimates
and risk of publication bias (Schünemann 2011b). We presented
the following outcomes in the Summary of findings for the main
comparison.
• Incidence of MUC
◦ BI stents
◦ PU stents
• Incidence of UTI
◦ BI stents
◦ PU stents
R E S U L T S
Description of studies
Results of the search
After searching the Specialised Register we identified 19 records.
Five studies (16 records) were included (Gunawansa 2011; Huang
2012; Indu 2012; Parapiboon 2012; TrUST 2017), one study
(one record) was excluded (Yari 2014), and two ongoing studies
were identified (ACTRN12610000349044; ISRCTN51276329).
These ongoing studies will be assessed in a future update of this
review (Figure 1). Three of the five authors were contacted for
further information regarding study design and results, one author
responded to our enquiries.
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Figure 1. Flow chart of study selection
Included studies
Five RCTs were included in the study with a total of 1127 patients.
The studies were heterogeneous in nature, including living and
deceased donors, adults and children, and varying definitions of
what was defined as ’early’ stent removal. This is summarised in
detail in the Characteristics of included studies.
Participants
The 1127 patients in the analysis included adult and paediatric
kidney transplant recipients. Themajority of studies included only
adults, while TrUST 2017 included both adults and children. The
mean age was 40.4 years in the early removal group and 42.2 years
in the late removal group. The type of donor varied: Indu 2012
and Gunawansa 2011 included only live donor recipients; Huang
2012 included only deceased donors; and Parapiboon 2012 and
TrUST 2017 included both live and deceased donors. All live
donor nephrectomies were laparoscopic.
Interventions
All studies utilised prophylactic double-J ureteric stents placed
intraoperatively. Three studies (Indu 2012; Huang 2012;
Parapiboon 2012) preferred the BI stent technique; the stent was
removed by flexible cystoscopy at the defined post-operative date.
Two studies (Gunawansa 2011; TrUST 2017) used the PU stent
technique; the early removal participants had the stent anchored
to the urinary catheter intraoperatively and removed simultane-
ously on day 7 post-operatively. The participants in the control
arm of these studies received a standard BI stent. The definition
of early removal varied considerable between studies; the majority
of studies termed early removal at day 7 post-transplant. How-
ever, Huang 2012 study included early removal up to day 21. Un-
usually, the length of stay in this study was longer than routine,
around 3 to 4 weeks. Equally, the author’s definition of early re-
moval was longer than our original, day 21 compared to day 15.
Despite this discrepancy with our protocol we decided to include
this study in the meta-analysis as the early stent removal time was
comparable bearing in mind the relatively increased length of stay
and the “intention to treat” fitted with our research question.
Outcomes
To investigate for MUC routine imaging (DTPA or ultrasound)
was performed by two of the five studies (Indu 2012; TrUST
2017). The other studies investigated for the presence of aMUC if
clinically indicated. AUTI was diagnosed based on the presence of
bacteriuria on regular routine urine sampling in four studies (Indu
2012; Huang 2012; Parapiboon 2012; TrUST 2017) irrespective
of symptoms. The remaining study (Gunawansa 2011) did not
describe this approach and did not respond to our request for
further information. The more idiosyncratic symptoms caused
by ureteric stents (e.g. haematuria, encrustation, migration and
irritation) were evaluated by two studies (Huang 2012; TrUST
2017). TrUST 2017 did a more in-depth analysis on participants
quality of life and health status as a result of early stent removal
using two separate validated questionnaires. The potential cost-
effective benefits of early stent removal was analysed by Parapiboon
2012.
In summary, the study designs were heterogeneous with varying
definitions of early or late stent removal. There was disparity in the
type of donor, recipient and length of follow up. Overall studies
were of an appropriate randomised controlled design comparing
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early with late ureteric stent removal. The nature to which the
studies focused on our primary outcome, major urological out-
comes, varied but all identified this as an important factor for in-
vestigation.
Excluded studies
One study was excluded (Yari 2014). This study was excluded
as only an abstract was available with very limited information
regarding the number of patients in each of the three intervention
arms therefore making analysis impossible. The authors did not
respond to our attempts at contact for further information.
Risk of bias in included studies
There was a moderate degree of bias across all included stud-
ies attributed to varying sources. It is unclear how many stud-
ies made an attempt to formally randomise patients using appro-
priate computer programs and sealed allocation as most studies
did not provide any information on these processes. As expected
none of the studies attempted to blind participants or personnel
to the intervention or to the outcome assessment. The majority
of studies detailed complete follow-up of all participants involved
in study, however, only one study include a CONSORT flow di-
agram (TrUST 2017). There were few published protocols of the
studies available for comparison with published data therefore at-
tributing the degree of reporting bias was problematic (Figure 2;
Figure 3).
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
Gunawansa 2011 and Huang 2012 contained no information and
did not respond to further requests for information regarding ran-
domisation and allocation. Three studies (Indu 2012; Parapiboon
2012; TrUST 2017) describe a robust randomisation process.
• Indu 2012 randomised using computer-generated random
numbers, placed into sealed opaque envelopes that were opened
on day 7 after transplant by nurses on the ward and determined
the allocation to either intervention arm. any participant who
developed a leak, delayed graft function, or rejection prior to
randomisation on day 7 was excluded. Both groups were
receiving a BI stent and were not yet randomised to a particular
arm therefore these exclusion criteria, although initially
appearing unusual actually have no bias effect on outcome.
• Parapiboon 2012 described a computer-generated block of
4 randomisation process, with allocation concealment by sealed
opaque envelopes.
• TrUST 2017 utilised an online randomisation program
which was block stratified for age with randomly varying block
sizes. Allocation was revealed to clinicians at the time of
randomisation.
Blinding
As expected, none of the studies blinded participants or person-
nel to their allocated intervention. Equally, none of the studies
attempted to blind personnel undertaking outcome assessments.
This may represent a high risk area for detection bias as those
clinicians caring for participants who were known to still have a
ureteric stent in situ may have beenmore concerned about the risk
of UTI and therefore sent urine samples more frequently leading
to over diagnosis and treatment of asymptomatic bacteriuria.
Incomplete outcome data
Follow-up of participants in the included studies was complete for
four studies (Huang 2012; Indu 2012; Parapiboon 2012; TrUST
2017). In these studies all patients were accounted for, however,
only TrUST 2017 included a CONSORT diagram. Gunawansa
2011 had limited information available from the published ab-
stracts and the authors did not respond to requests for further in-
formation.
Selective reporting
The majority of studies included did not have published study
protocols available for comparison. TrUST 2017 published a pro-
tocol and it appears they have fully reported on all anticipated out-
comes. Huang 2012 and Indu 2012 fully reported all outcomes.
Gunawansa 2011 had limited information available based from
the published abstracts and the author did not respond to requests
for further information. Parapiboon 2012 did not report in detail
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the MUC encountered. These consisted of two patients in each
intervention group, but there is no further detail as to the nature of
this complication or what they deem to be aMUC. This study has
published two papers; one focusing on the incidence of bacteriuria
and the other a cost-benefit analysis. The incidence of UTI data is
very detailed and well reported as this was their primary outcome
of interest. MUC were not a priority in this study and as such
there is very little detail reported on complications encountered
potentially resulting in a degree of reporting bias.
Other potential sources of bias
Huang 2012 was judged to be at high risk of other potential bias
due to the very long length of stay whichmay be associated with an
increased risk of nosocomial infection. Three studies appeared to
be free of other potential sources of bias (Indu 2012; Parapiboon
2012; TrUST 2017), and Gunawansa 2011 was judged unclear
as there was insufficient information reported in the conference
abstracts.
Effects of interventions
See: Summary of findings for the main comparison Early versus
late ureteric stent removal after kidney transplantation
Major urological complications
It is uncertain whether early versus late stent removal makes any
difference to MUC (Analysis 1.1 (5 studies, 1127 participants):
RR 1.87, 95%CI 0.61 to 5.71; I2 = 21%; low certainty evidence).
Heterogeneity between studies was deemed to be low.
There was little or no difference in MUC when either BI stents
(Analysis 1.1.1 (3 studies, 539 participants): RR 1.67, 95% CI
0.52 to 5.36; participants = 539; studies = 3; I2 = 0%) or PU stents
(Analysis 1.1.2 (2 studies, 588 participants): RR 1.51, 95% CI
0.03 to 74.45; participants = 588; studies = 2; I2 = 78%) where
used (test for subgroup differences: Chi² = 0.00, df = 1 (P = 0.96),
I2 = 0%).
Urinary tract infection
The incidence ofUTI varied greatly between studies, ranging from
2.2% to 73%. Early stent removal may reduce the number of UTI
compared to late removal (Analysis 2.1 (5 studies, 1126 partici-
pants, RR 0.49 95% CI 0.30 to 0.81; I2 = 59%; moderate cer-
tainty evidence). These findings are within a markedly heteroge-
neous group, where the incidence and definition of UTI was very
variable. The test for heterogeneity was moderate.
Patients were probably less likely to develop a UTI with early
removal compared to late removal of a BI stent (Analysis 2.1.1
(3 studies, 539 participants): RR 0.45 95% CI 0.29 to 0.70; I
2 = 13%; moderate certainty evidence). There was little or no
difference in UTI with early versus late PU stent removal (Analysis
2.1.2 (2 studies, 588 participants): RR 0.60, 95%CI 0.17 to 2.03;
I2 = 83%; low certainty evidence). Of note, there was substantial
heterogeneity with PU stents.
Minor stent-related complications
Only Huang 2012, Indu 2012 and TrUST 2017 examined mi-
nor stent-related complications in more detail (e.g. haematuria,
encrustation, migration). Huang 2012 found these complications
were significantly more likely to occur in the late stent removal
group. For example, irritative symptoms were experienced in 42/
186 patients in the late group compared to 16/179 in the early
group (P = 0.001). This study also reported 3 cases of ’forgotten
stents’ that resulted in removal at a much later date (12 weeks).
Indu 2012 examined the incidence of stent migration, breakage
and haematuria and found no cases in either the early or late stent
removal group. In TrUST 2017, the late stent removal group expe-
rienced more pain (0/80 in early group versus 4/126 in late group;
P = 0.259), more episodes of haematuria (0/80 early versus 2/126
in the late group; P = 0.666), andmore episodes ofmigration (0/80
early versus 3/126 in the late group; P = 0.409). The TrUST 2017
investigators also evaluated participants health status and quality
of life using FAIT-U and EQ-5D questionnaires. They found no
difference at week one post-transplant, however, by week six the
health status scores (FAIT-U) were significantly better in those
patients who had their ureteric stent removed early (P = 0.012).
Cost-effectiveness
Only Parapiboon 2012 examined the cost effectiveness of early
stent removal. In this study (intention-to-treat analysis) patients
whose stent was removed at seven days were significantly less likely
to develop a UTI (15/37, 40.5% versus 27/37, 72.9%; P = 0.004).
According to figures from their centre, the mean hospital cost,
including accommodation, investigations and treatment, for pa-
tients with a UTI was significantly higher than those without a
UTI (11,890 USD versus 6897 USD, P < 0.001). The mean cost
of early ureteric stent removal was lower than routine removal
(8792 USD versus 11,182 USD; P = 0.06). With early ureteric
stent removal the authors estimated a saving of 2390 USD per
kidney transplant recipient.
D I S C U S S I O N
Summary of main results
Universal use of ureteric stents in kidney transplantation has sig-
nificantly reduced the incidence of MUC (Wilson 2013). How-
ever, they are associated with other risks such as UTI, haema-
turia, encrustation and irritative bladder symptoms. These risks
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are likely to increase in incidence the longer the stent is in place.
It is uncertain whether ureteric stents can be safely removed at an
earlier time point than traditionally accepted without any increase
in risk of MUC (RR 1.87, 95% CI 0.61 to 5.71). There may be
a reduction in the incidence of UTI with early stent removal (RR
0.49 95% CI 0.30 to 0.81). The incidence of UTI in the late stent
removal group from this set of studies is directly comparable to
the summative stented cohort from the meta-analysis by Wilson
2013.
Our analysis also identified that the associated reduction in UTI
incidence was only seen BI stents (RR 0.45, 95%CI 0.29 to 0.70).
In those studies where the ureteric stent was tied to the urinary
catheter the benefit of early stent removal was lost (RR 0.60 95%
CI 0.17 to 2.03). This may be due to the externalisation of the
indwelling stent providing an easy track for antimicrobial coloni-
sation. TrUST 2017, which utilised the PU stent method in their
early removal arm, reported reasonably high treatment failure rate
using this technique (15). This was reported as due to technical
difficulties attaching the stent to catheter. This resulted in conver-
sion of a PU stent to a BI stent and these stents were subsequently
removed at the later time point six weeks post-operatively (Table
1).
One study reporting cost effectiveness estimated a saving of 2390
USD per patient with early stent removal.
Overall completeness and applicability of
evidence
This review identified only a small number of studies for which
limited information was available despite contacting the authors
directly. All of the included studies provided information regard-
ing our primary outcome of interest, MUC, and the secondary
outcome UTI. Only three studies provided further information
regarding other stent associated complications and, although not
statistically significant, two of these studies noted a reduction in
pain, haematuria, migration and encrustation of stents if they
were removed early. Also of note, there are a number of ongo-
ing studies which were not included and may provide more im-
portant information in the future (ACTRN12610000349044;
ISRCTN51276329).
Our sensitivity analysis did not reveal any untoward influence on
effect size when taking into account the filters described earlier in
ourmethods section; excluding unpublished studies, excluding the
largest studies, excluding studies with aberrant diagnostic criteria
and excluding studies with a different language of publication. We
also examined the data using a “worst-case” scenario approach and
this revealed that our conclusion is robust enough to withstand
wide variations in data.
Quality of the evidence
The studies included in the review were generally of poor quality,
with only three studies reporting a robust randomisation process
(Indu 2012; Parapiboon 2012; TrUST 2017). With the limited
information available it was difficult to assess to risk of bias for a
few of the studies and these were assumed to be high risk. Due to
the nature of the intervention blinding was not possible but this is
unlikely to have affected outcome. Across included studies there is
a relatively short follow-up period, median four months, but this
is still likely to have captured the outcomes of concern, MUC and
UTI.
There was a substantial degree of heterogeneity within the studies
when examining UTI incidence, due to the differences in each
individual study’s definition of UTI. Some studies included all
bacterial urinary colonisation irrespective of symptoms and others
only included symptomatic patients. However, when investigating
an immunosuppressed transplant recipient population any degree
of bacteriuria is significant to warrant concern and therefore a
change to practice, in this case earlier stent removal, which can
minimise this risk, is of benefit.
Potential biases in the review process
In conducting a meta-analysis there is an inherent risk of publi-
cation bias due to the retrospective nature of the search. To min-
imise this risk we searched multiple databases without language
restriction and utilised the Cochrane Kidney and Transplant Spe-
cialised Register to gain access to reports of studies only presented
at conferences and meetings. The data presented is up to date as
of March 2017 and the ongoing studies discovered in the search
were still unpublished prior to our publication. However, in an at-
tempt to minimise publication bias, we have included studies only
published as a conference abstract which have not been through a
robust peer review process. Four of the five studies included were
published in peer reviewed journals. The studies included overall
have a moderate degree of bias which we have attempted to min-
imise through developing a detailed protocol for analysis prior to
commencing this study.
Agreements and disagreements with other
studies or reviews
To our knowledge there are no other meta-analyses or systematic
reviews addressing this issue.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
It is uncertain whether early removal of ureteric stents following
kidney transplantation is associatedwith a higher risk ofMUCand
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may reduce the incidence of UTI in an immunosuppressed patient
population. This benefit is only realised if the ureteric stent is BI
as opposed to externalised and attached to the patient catheter.
Implications for research
A cost-benefit analysis would be valuable further research when
considering early stent removal. It would interesting to include
patient quality of life questionnaires as irritative bladder symptoms
are a considerable source of patient complaint often ignored as
a necessary evil by clinicians. Early removal would minimise this
discomfort to patients and decrease the disruption and cost of
a return appointment for stent removal at a later date. This has
been addressed in TrUST 2017 but needs wider validation. We
need more evidence to conclude exactly which early technique is
better, BI versus PU versus PC, as there were a limited number
of studies in each of these arms. It would also be beneficial to
understand potential categories of patients in which early removal
is not advised due to an inherent increased risk of MUC.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Gunawansa 2011
Methods • Study design: parallel RCT
• Study duration: January 2009 and August 2013
• Duration of follow-up: mean 16 (12 to 36) months
Participants • Country: Sri Lanka
• Setting: single-centre
• Live donor kidney transplants for recipients with ESKD
• Number: treatment group (203); control group (179)
• Mean age ± SD (years): not reported
• Sex (M/F): not reported
• Exclusion criteria: not stated
Interventions Treatment group
• Early stent removal of PU stent tied to tip of urinary catheter intraoperatively and
removed simultaneously with the catheter at the bedside at day 6
Control group
• Late stent removal via flexible cystoscopy at day 28
Outcomes • MUC (ureteric anastomotic stenoses)
• UTI
Notes • Abstract-only publications; no response from author regarding requests for
further information
• Prospectively followed up for MUC & UTI, no other detailed information
available
• Funding source: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information to permit judge-
ment
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
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Gunawansa 2011 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
Other bias Unclear risk Insufficient information to permit judge-
ment
Huang 2012
Methods • Study design: parallel RCT
• Study duration: January 2009 to December 2010
• Duration of follow-up: 3 months minimum
Participants • Country: China
• Setting: single centre
• Deceased donor for adult ESKD recipients
• Number: treatment group (179); control group (186)
• Mean age ± SD (years): treatment group (42.8 ± 7.5); control group (43.5 ± 8.1)
• Sex (M/F): treatment group (133/46); control group (137/49)
• Exclusion criteria: not reported
Interventions Treatment group
• Early removal at week 3 post-op
Control group
• late removal at week 6 post-op
Other information
• Stent type: double-J stent, BI
• Stent calibre: 5 Fr 15cm
• Removed using flexible cystoscopy and local anaesthetic
Outcomes • MUC: urological complications defined as any cause requiring PC nephrostomy
or surgical revision (e.g. urinary fistula, leakage, ureteral obstruction)
• UTI
• Other stent related complications: duration of macroscopic haematuria, incident
so of malposition or calculus formation
Notes • Short follow-up
• Definition of early removal is 3 weeks as opposed to < 15 days
• Funding source: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
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Huang 2012 (Continued)
Random sequence generation (selection
bias)
Unclear risk Insufficient information to permit judge-
ment “...were randomly assigned to two
groups”
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding but unlikely to affect outcome
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk All patients accounted for:
- 3 patients forgot to return for stent re-
moval at 6 weeks and it was removed at 12
weeks
- 4 patients removed from analysis (2 in
each group) due to stent migration
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias High risk Very long length of stay 3 to 4weeks,maybe
associated with increased risk of nosoco-
mial infection
Indu 2012
Methods • Study design: parallel RCT of 100 consecutive patients
• Study duration: January 2007 and December 2009
• Duration of follow-up: 6 months minimum
Participants • Country: India
• Setting: single centre
• Living donor kidney transplant (laparoscopic donor nephrectomy) for ESKD
• Number: treatment group (50); control group (50)
• Mean age ± SD (years): treatment group (34.4 ± 10.5); control group (33.8 ± 10.
4)
• Sex (M/F): treatment group (38/12); control group (40/10)
• Exclusion criteria: if within 7 days patient developed urine leak, DGF or rejection
prior to randomisation on day
Interventions Treatment group
• Early removal at day 7 post-op
Control group
• Late removal at day 28 post-op
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Indu 2012 (Continued)
Other information
• Stent calibre: 4Fr 16cm
• Stent type: double J, BI
• Removal: flexible cystoscopy, local anaesthetic and IV ceftazidime for
antimicrobial cover
• Urinary catheter removed day 6
Outcomes • UTI
• Asymptomatic bacteriuria
• MUC
• MSU sent routinely on day 7, at 3 weeks, 3 months and 6 months and at any
other time if symptomatic
• USS routinely performed on day 5, 4 weeks, 3 months and 6 months or if there
was a rise in SCr
• DTPA renogram routinely on day 5 and 6 months post-op
Notes • Funding source: nil
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised by computer generated ran-
dom numbers created by study coordinator
Allocation concealment (selection bias) Low risk Allocation kept in sealed opaque envelopes
until opened on day 7 by ward nurses
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding but unlikely to impact out-
come
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data, however CON-
SORT diagram not included
Selective reporting (reporting bias) Low risk No study protocol data but all reported out-
comes are accounted for
Other bias Low risk The study appears to be free of other biases
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Parapiboon 2012
Methods • Study design: parallel RCT
• Study duration: April 2010 to January 2011
• Study follow-up period: not reported
Participants • Country: Thailand
• Setting: single-centre
• Living and deceased donors (58% living) for adult ESKD recipients
• Number: treatment group (37); control group (37)
• Mean age ± SD (years): treatment group (42.7 ± 12.4); control group (43.8 ± 14.
1)
• Sex (M/F): treatment group (24/13); control group (27/10)
• Exclusion criteria: neurogenic lower urinary tract disease; abnormal anatomy; en
bloc paediatric donors; CIT > 36 h
Interventions Treatment group
• Early removal day 7 post-op
Control group
• Late removal day 14 post-op
Other information
• Stent calibre: 6FR 26 cm
• Stent type: double-J stent, BI
• Removal: flexible cystoscopy with local anaesthetic
• Bladder catheter for 7 days
Outcomes • MUC
• UTI (defined as either asymptomatic, symptomatic or urosepsis)
• Routine MSU testing at day 0, 3, 7, 10, 14 and twice weekly until discharge
• Radioisotope scanning at 1 and 2 month post-op to detect urological
complications
Notes • No information on type of urological complication encountered
• Includes cost-benefit analysis.
• Funding source: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated block of 4
Allocation concealment (selection bias) Low risk Sealed opaque envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinding not possible but unlikely to affect
outcome
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Parapiboon 2012 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No evidence of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk All patients accounted for but no CON-
SORT diagram
Selective reporting (reporting bias) High risk No information on what type of urological
complications were encountered
Other bias Low risk The study appears to be free of other biases
TrUST 2017
Methods • Study design: parallel RCT; block-stratified for age (2 to 16 years; 17 to 75 years)
• Study duration: April 2010 to October 2013
• Duration of follow-up: minimum 6 months
Participants • Country: UK
• Setting: multicentre (6)
• Living and deceased donors; adult and paediatric ESKD recipients
• Number (analysed/PP population): treatment group (80/81); control group (126/
131)
• Median age, IQR (years): treatment group (47.5, 31.1 to 58.0); control group
(41.7, 24.2 to 53.8)
• Sex (M/F): treatment group (54/27); control group (93/37)
• Exclusion criteria: increased risk of bleeding; abnormal urinary tract anatomy or
function; planned early use of mTORi; stones
Interventions Treatment group
• Early removal group had a ureteric stent attached to the urethral catheter
intraoperatively and then removed non-invasively on day 5 to 7
Control group
• Late removal group had a J-J stent placed routinely intraoperatively and it was
removed at approximately 6 weeks cystoscopically
Other information
• Stent calibre: 6FR/16cm for adults, 4.8-6Fr/16cm for children
• Stent Type: Double J stent
• Bladder catheter for 75 days
Outcomes • MUC (ureteric leaks, ureteric stenosis; “intermediate urological complications” i.
e. oedema or clot causing obstruction that had to be managed by nephrostomy) (80
patients analysed in the early removal group)
• UTI (79 patients in the early removal group analysed)
Notes • Study not powered to assess MUC
• 15 cases of failure to tie catheter to stent due to technical difficulty
• 21 patients in the early group failed to receive the allocated treatment and were
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TrUST 2017 (Continued)
regarded as crossovers into the late group, undergoing late stent removal
• Investigated effect of early removal on idiosyncratic stent complications and QoL
• Funding source: NIHR and Guy’s and St Thomas’ Charity
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Online computer generated randomisation
process, block stratified with randomly
varying block sizes
Allocation concealment (selection bias) Low risk Allocation revealed to clinicians at time of
randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinding not possible but unlikely to affect
outcome
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not possible
Incomplete outcome data (attrition bias)
All outcomes
Low risk CONSORT diagram included detailing
full follow-up
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Low risk The study appears to be free of other biases
BI - bladder indwelling; CIT - cold ischaemic time; DGF - delayed graft function; DPTA - diethylenetriaminepentaacetic acid; ESKD
- end-stage kidney disease; IQR - interquartile range; IV - intravenous; M/F - male/female; MSU - midstream urine; mTORi -
mammalian target of rapamycin inhibitor; MUC - major urological complications; PC - percutaneous; PU - per-urethral; PP - per
protocol; RCT - randomised controlled trial; SCr - serum creatinine; SD - standard deviation; USS - urinary ultrasound; UTI -
urinary tract infection
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Yari 2014 Not enough information included in abstract available regarding numbers of patients in intervention arms therefore
unable to include in analysis. Authors did not respond to our contact for more information
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Characteristics of ongoing studies [ordered by study ID]
ACTRN12610000349044
Trial name or title Pilot study: prospective randomised controlled trial of ureteric double J stenting with early vs standard stent
removal to improve graft and patient outcome and reduce urological complications after renal transplantation
Methods Prospective RCT comparing early removal of ureteric stent at day 4 (attached to catheter) compared to late
removal 4-6 weeks post-op cystoscopically
Participants All patients > 16 years on the kidney transplant waiting list at a single centre
Exclusion criteria: neurogenic bladder dysfunction or re-transplant
Interventions Double J stent sutured to urinary catheter and removed simultaneously on day 4 post-transplant
Outcomes Primary outcome (1): graft outcome assessed using histology from renal biopsy, SCr and eGFR
Primary outcome (2): at 12 months post-transplant patient mortality data will be recorded
Secondary outcome: MUC
Starting date 01/05/2010
Contact information Dr Adam Bartlett, adamb@adhb.govt.nz
Notes No outcome data to be obtained regarding UTI
ISRCTN51276329
Trial name or title Randomised controlled trial of early versus late ureteric stent removal post kidney transplant
Methods Parallel RCT
Participants Sample size set at 350 based on power calculations. To include all adults receiving at kidney either living or
deceased donor
Interventions Group A - removal of ureteric stent on day 6-8 post-transplant
Group B - removal of ureteric stent during week 4-6 post-transplant
Outcomes Primary outcome: composite incidence of UTI and ureteric complications
Secondary outcome: incidence of UTI, urine leak, stenosis, patient death, graft loss, surgical complications,
immunological complications, readmission and length of stay, medical complications
Measure at 3 months post-transplant
Starting date 1/1/2014
Contact information Dept of Surgery Addenbrookes
Notes
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eGFR - estimated glomerular filtration rate; MUC - major urological complications; RCT - randomised controlled trial; SCr - serum
creatinine; UTI - urinary tract infection
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D A T A A N D A N A L Y S E S
Comparison 1. Major urological complications
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Major urological complications 5 1127 Risk Ratio (M-H, Random, 95% CI) 1.87 [0.61, 5.71]
1.1 Bladder indwelling stents 3 539 Risk Ratio (M-H, Random, 95% CI) 1.67 [0.52, 5.36]
1.2 Per-urethral stents 2 588 Risk Ratio (M-H, Random, 95% CI) 1.51 [0.03, 74.45]
Comparison 2. Urinary tract infection
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Urinary tract infection 5 1126 Risk Ratio (M-H, Random, 95% CI) 0.49 [0.30, 0.81]
1.1 Bladder indwelling stents 3 539 Risk Ratio (M-H, Random, 95% CI) 0.45 [0.29, 0.70]
1.2 Per-urethral stents 2 587 Risk Ratio (M-H, Random, 95% CI) 0.60 [0.17, 2.03]
A D D I T I O N A L T A B L E S
Table 1. Reported adverse events
Study ID Adverse events
Gunawansa 2011 Two patients in the late group required re-stenting due to ureteric stenosis
Huang 2012 Three patients in the late group had forgotten stents that were subsequently removed at 12 weeks
Indu 2012 Six patients in the early and 5 patients in the late group had acute rejection that required intervention
Parapiboon 2012 No adverse events reported
TrUST 2017 Sixteen patients did not receive their allocated treatment as there were technical difficulties attaching the stent
to the catheter
In the early removal group, 1 patient’s stent removal was delayed by 1 day because the urethral catheter balloon
needed percutaneous needle puncture due to the stent suture
There were 5 complications in patients who had early stent removal and these were all related to the percutaneous
technique used in which the stent was tied to the catheter
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
There were no identified studies that utilised the PCmethod of stent placement and therefore this subgroup analysis that was included in
the protocol could not be included. Only two studies included examined in any detail the incidence of idiosyncratic stent complications
(e.g. bladder irritation, haematuria, encrustation) and therefore a robust meta-analysis could not be performed.
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